Skip to content

EsoBiotec

Active Public limited companyfounded 2020active for 6 yearsRue André Dumont 5, 1435 Mont-Saint-GuibertKBO/BCE: BE 0756.885.159 subsidiary of #4 company by equity in Walloon Brabant, Research and development sector

Annual accounts 2025

abbreviated format, filed on 07-07-2026, 24 days before the deadline
€26.8m
▲ €27.5m
€11.1m
▲ €18.2m
€7.7m
▲ €14.6m
€12.4m
▲ 771%
75.3%
▲ 40.4 percentage points
4.07
▲ 2.32

Turnover is estimated at about €46.0m, probably between €31.0m and €76.0m.

Balance sheet

balance sheet total €16.5m on 31-12-2025
What the company ownsHow it is paid for

in €m

in €m

Position in the sector

75.3%

Higher than 73% of the 346 companies filing abbreviated accounts in research and development (NACE 72) in 2025.

4.07

Higher than 70% of the 327 companies filing abbreviated accounts in research and development (NACE 72) in 2025.

46.9%

Higher than 95% of the 339 companies filing abbreviated accounts in research and development (NACE 72) in 2025.

EsoBiotec Middle half of the sector 80% of the sector Abbreviated accounts in research and development (NACE 72)

Net result: top quarter · Equity: top quarter · Balance sheet total: top quarter · Working capital: top quarter · Staff: middle half

Staff

€278,692

Staff costs divided by the average number of full-time equivalents.

-12 employees

employees who joined employees who left

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend2025202420232022202114 months
18.0m-1.8m-976,2301.5m-180,495
14.7m-1.5m-913,8441.5m-182,518
6.8m5.3m1.5m4.0m509,183
-1.2m-95,822-2.7m964,648-
12.4m1.4m4.8m4.8m3.8m
75.3%35.0%36.5%69.3%48.6%
4.071.768.3810.009.26
0.331.861.740.441.06
62.3%-457.4%-112.4%-19.9%-8.6%
46.9%-160.0%-41.1%-13.8%-4.2%
50.29-57.04-25.8465.18-88.28

EBIT margin not included in this filing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend2025202420232022202114 months
Balance sheet: assets
20/58 16.5m4.3m6.5m7.3m4.7m
21/28 501980,7991.1m1.9m481,483
21 ---682,638449,509
22/27 -979,7351.1m1.2m31,116
23 -209,454219,285240,779-
24 -319,205369,468993,24731,116
25 -451,076508,579--
28 5011,0641,0641,284858
29/58 16.5m3.3m5.4m5.4m4.3m
40/41 16.4m547,8371.5m1.2m1.1m
40 -32,01021,79110,07012,921
41 16.4m515,8271.4m1.2m1.1m
50/53 -1.4m2.5m--
54/58 113,1831.3m1.4m4.1m3.2m
490/1 -51,38345,9145,1233,156
Balance sheet: equity and liabilities
10/49 16.5m4.3m6.5m7.3m4.7m
10/15 12.4m1.5m2.4m5.1m2.3m
10/11 15.4m12.3m6.3m6.3m2.5m
10 15.4m12.3m6.3m6.3m2.5m
100 15.4m12.3m6.3m6.3m2.5m
14 -3.0m-10.7m-3.9m-1.2m-198,317
17/49 4.1m2.8m4.1m2.2m2.4m
17 -905,2012.5m615,686-
170/4 -905,2012.5m615,686-
42/48 4.0m1.9m645,837536,801459,553
42 -231,943220,770176,435-
44 398,1381.1m358,116305,305459,458
440/4 398,1381.1m358,116305,305459,458
45 3.7m192,39266,85654,751-
450/3 3.6m42,532-62-
454/9 1,189149,86066,85654,689-
47/48 -377,9119531095
492/3 18,220-997,8091.1m2.0m
Income statement
76A 42.6m----
9900 26.8m-761,751483,6542.2m82,332
62 2.6m1.0m892,857697,557262,827
630 6.9m5.4m1.8m2.5m15,800
640/8 104,100----
66A 6.0m-567,027--
9901 11.1m-7.2m-2.7m-1.1m-196,295
75/76B 1.1m54,11627,873322
75 1.1m54,11627,873322
65/66B 358,25431,20237,78022,6872,045
65 358,25431,20237,78022,6872,045
9903 11.8m-7.1m-2.7m-1.1m-198,317
67/77 4.1m-268,289-72,294-80,792-
9904 7.7m-6.9m-2.7m-1.0m-198,317
9905 7.7m-6.9m-2.7m-1.0m-198,317
Appropriation of the result
9906 -3.0m-10.7m-3.9m-1.2m-198,317
14P -10.7m-3.9m-1.2m-198,317-
Social balance sheet
9087 9.410.69.673.2
Hours worked1013 14,79417,68116,60412,3405,904
Document PDFPDFPDFPDFPDF

The full notes are in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 07-07-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 abbreviated format 07-07-2026 2026-00275331 PDF
31-12-2024 full format 08-07-2025 2025-00241917 PDF
31-12-2023 micro format 27-06-2024 2024-00168882 PDF
31-12-2022 micro format 29-06-2023 2023-00173621 PDF
31-12-2021 micro format 05-07-2022 2022-20151103 PDF

Social balance sheet

Item31-12-202531-12-202431-12-202331-12-202231-12-2021
Employees at the balance-sheet date-121095
full-time-11995
part-time-110-
in full-time equivalents-11.89.695
9.410.69.673.2
On a permanent contract-11995
Joined14586
Left132441

Source: social balance sheet in the 2021 to 2025 annual accounts

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets-€27,022€7,549€1.3m€32,341
Intangible fixed assets€6.8m€5.2m€1.5m€2.7m€475,984
Financial fixed assets--€125€606€858
€6.9m€5.4m€1.8m€2.5m€15,800

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on EsoBiotec

The operating result for 2025 is a profit of €11.1m, after a loss of €7.2m in 2024. It is the highest result since 2022.

Debt's share of the balance-sheet total falls from 65.0% to 24.7%. Equity and debt are higher.

Large changes and their cause
  • 2024 Compared with 2023, the net result fell by 157%. The accounts now follow the full format, last year the micro format.
  • 2022 Compared with 2021, the net result fell by 406%. The previous financial year ran 14 months, this one 12.
  • 2022 Compared with 2021, equity rose by 119% and the balance sheet total by 54%. Capital increase of €3.8m (Official Gazette 16-06-2022).

Next steps